Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.Bello, A.M., Konforte, D., Poduch, E., Furlonger, C., Wei, L., Liu, Y., Lewis, M., Pai, E.F., Paige, C.J., Kotra, L.P.
(2009) J Med Chem 52: 1648-1658
- PubMed: 19260677
- DOI: https://doi.org/10.1021/jm801224t
- Primary Citation of Related Structures:
3G3D, 3G3M, 3S9Y
- PubMed Abstract:
A series of 6-substituted and 5-fluoro-6-substituted uridine derivatives were synthesized and evaluated for their potential as anticancer agents. The designed molecules were synthesized from either fully protected uridine or the corresponding 5-fluorouridine derivatives. The mononucleotide derivatives were used for enzyme inhibition investigations against ODCase. Anticancer activities of all the synthesized derivatives were evaluated using the nucleoside forms of the inhibitors. 5-Fluoro-UMP was a very weak inhibitor of ODCase. 6-Azido-5-fluoro and 5-fluoro-6-iodo derivatives are covalent inhibitors of ODCase, and the active site Lys145 residue covalently binds to the ligand after the elimination of the 6-substitution. Among the synthesized nucleoside derivatives, 6-azido-5-fluoro, 6-amino-5-fluoro, and 6-carbaldehyde-5-fluoro derivatives showed potent anticancer activities in cell-based assays against various leukemia cell lines. On the basis of the overall profile, 6-azido-5-fluoro and 6-amino-5-fluoro uridine derivatives exhibited potential for further investigations.
Center for Molecular Design and Preformulations and Division of Cellular and Molecular Biology, Toronto General Research Institute, Toronto General Hospital, Toronto, Ontario M5G 2C4, Canada.